Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + Toripalimab + GEMOX in Biliary Tract Cancer
NCT06654947Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of surufatinib in biliary tract cancer (BTC), sponsored by Fujian Medical University Cancer Hospital. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06654947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06654947.